🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseSurvodutide SYNCHRONIZE Phase 3 — November 2025 Page 6

Survodutide SYNCHRONIZE Phase 3 — November 2025

ZaraB_AL Thu, Sep 12, 2024 at 4:18 AM 56 replies 2,243 viewsPage 6 of 12
mike.trainer_LA
Senior Member
1,567
7,234
Apr 2024
Los Angeles, CA
Nov 6, 2024 at 3:04 AM#26

A narrower follow-up, since the general answer is now clear:

How would you tell the difference between that and the alternative explanation?

Last edited: Nov 6, 2024 at 7:04 AM
40 13Dr.AddMedPHL, newstart_MO, mia_MS2 and 37 others
Reply Quote Save Share Report
emma_london
Member
312
1,456
Oct 2024
London, UK
Nov 13, 2024 at 4:01 AM#27
DataDave said:
If you are going to change something, change one thing and give it long enough to express itself.

This is where I part company with the consensus forming above. Not convinced. The evidence being cited is consistent with the conclusion and also consistent with two other conclusions nobody has ruled out.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

41 14mike.trainer_LA, sarah_nash92, FitDadDave and 38 others
Reply Quote Save Share Report
lisa_labSD
Member
278
1,234
Oct 2024
San Diego, CA
Nov 20, 2024 at 4:54 AM#28
DataDave said:
If you are going to change something, change one thing and give it long enough to express itself.

That is right for the common case. Whether it is right for the case being asked about depends on a detail that has not been given.

Worth separating that from the trial evidence, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

42 15Dr.PulmRoch, maya_sedona, stefan_berlin and 39 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
NeuroNate
Senior Member
2,890
16,789
Dec 2023
Chicago, IL
Nov 27, 2024 at 5:43 AM#29
DataDave said:
If you are going to change something, change one thing and give it long enough to express itself.

That reframing is the part I needed. Sending this to two other people who asked me the same thing last week.

43 16kim_atl_prep, sarah_TO, wendy_avl and 40 others
Reply Quote Save Share Report
ZaraB_AL
Member
456
1,678
Jan 2025
Alabama
Dec 4, 2024 at 6:28 AM#30

Reporting back.

Update — my curve sits below the published mean and the explanation is that the trial arm had support I do not have. That was reassuring rather than otherwise.

Last edited: Dec 4, 2024 at 7:28 AM
15 13JennaRN, LabKate, kate.chem and 12 others
Reply Quote Save Share Report
14567812

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register